Kymera Therapeutics, Inc. Common Stock (KYMR)
Health Care – BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
- Headquarters
- United States
- Employees
- 253
- Market Cap
- $8.2B
About Kymera Therapeutics, Inc. Common Stock
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.
Kymera Therapeutics, Inc. Common Stock stock analysis, sentiment tracking, and market intelligence on SentiSense.